Streetbeat News

Products Services

CHRS

Coherus BioSciences' stock is trading higher following the announcement of FDA approval for UDENYCA ONBODY, a pegfilgrastim-cbqv product.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 1:46 pm

FWBI

SNY

First Wave BioPharma, Inc. (FWBI) shares surged after announcing a non-binding term sheet to sell its Niclosamide program for IBD treatment to an undisclosed biopharmaceutical company. The deal includes a low seven-figure upfront payment, future milestones, and royalties. This allows FWBI to concentrate on its late-stage clinical programs, including those licensed from Sanofi (SNY). The transaction is expected to close in the first half of 2024, and FWBI shares rose 143% premarket.

Portfolio Pulse from Nabaparna Bhattacharya

December 27, 2023 | 1:40 pm

CDXS

Codexis, Inc. (NASDAQ:CDXS) has entered into a purchase agreement with Nestlé Health Science for CDX-7108, a therapy for exocrine pancreatic insufficiency (EPI). Codexis will receive up to $45M in milestone payments, including a $5M upfront payment and single-digit net-sales-based royalties. An additional $5M is possible if Nestlé exercises an option for two more early-stage enzymes. Nestlé will handle further development and commercialization, while Codexis focuses on its ECO Synthesis platform and Pharmaceutical Manufacturing business growth.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 1:33 pm

BTCT

BTC Digital Ltd. (NASDAQ:BTCT) has entered into a service agreement to manage and provide technical services for 1,480 Bitcoin mining machines for a significant client. The machines include AntS19Jpro+ and M50 models, and the services will be deployed in the United States. This agreement is expected to enhance BTCT's growth and presence in the cryptocurrency mining industry, with potential further collaboration with the client in this sector.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 1:32 pm

VTGN

Vistagen Therapeutics (NASDAQ: VTGN) is set to receive a patent from the European Patent Office for AV-101, a treatment for neuropathic pain. Preclinical studies show AV-101 has effects similar to gabapentin but with fewer side effects. Phase 1 clinical trials indicate AV-101 is well-tolerated with no significant adverse events compared to placebo. The patent will extend until at least 2034, enhancing Vistagen's global patent portfolio. The company is seeking strategic collaborations to advance AV-101's clinical development and commercialization. The FDA has granted Fast Track designation for AV-101 as a non-opioid treatment for neuropathic pain.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 1:30 pm

F

LCID

RIVN

STLA

TSLA

On Christmas, several automakers including Tesla, Ford, Stellantis, Rivian, and Lucid Group used social media to extend holiday wishes, featuring their vehicles in festive posts. Tesla showcased its Cybertruck, Ford highlighted the Mustang, Stellantis featured Jeep, RAM, and Chrysler brands, Chrysler individually presented the Pacifica minivan, Rivian displayed the R1T truck, and Lucid chose the Air sedan over its new Gravity SUV.

Portfolio Pulse from Anan Ashraf

December 27, 2023 | 1:30 pm

CYTK

Cytokinetics' stock price has risen following the announcement of positive topline results from their Phase 3 SEQUOIA-HCM clinical trial of aficamten, a treatment for symptomatic obstructive hypertrophic cardiomyopathy.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 1:21 pm

MSFT

NYT

The New York Times has filed a lawsuit against OpenAI and Microsoft, alleging that millions of its copyrighted articles were used to train chatbots, which are now competing with the newspaper. The lawsuit claims infringement of copyright and seeks to address the competitive implications of AI-generated content.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 1:19 pm

MDGS

Medigus Ltd. (NASDAQ:MDGS) announced that its subsidiary, Charging Robotics, has successfully completed a key experiment in wireless high voltage electricity transfer for EV charging. This is a significant step towards implementing a wireless charging system in automated car parks. The experiment verified the proprietary control algorithms for voltage and current. The global Automated Parking System market is expected to grow from USD 1.8 billion in 2022 to USD 5.2 billion by 2032, with a CAGR of 11.4%. The growth in the EV market alongside automated parking suggests a promising future for this technology.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 1:13 pm

ENVB

Enveric Biosciences has reported progress on the preclinical development of its lead prodrug candidate, EB-373, as of year-end. The company anticipates completing all preclinical activities for EB-373 by Q1 of 2024, setting the stage for a first-in-human clinical trial.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 1:06 pm